Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Post-Mkt 12-05 19:39:12 EST

104.60

-1.10

-1.04%

盘后104.60

+0.000.00%

17:01 EST

High106.76	Low103.59	Vol539.92K
Open105.70	D1 Closing105.70	Amplitude2.99%
Mkt Cap6.98B	Tradable Cap5.59B	Total Shares66.74M
T/O56.58M	T/O Rate1.01%	Tradable Shares53.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":104.6,"timestamp":1764968400000,"preClose":105.7,"halted":0,"volume":539915,"hourTrading":{"tag":"盘后","latestPrice":104.6,"preClose":104.6,"latestTime":"17:01 EST","volume":5995,"amount":627039.80702,"timestamp":1764972074102},"delay":0,"floatShares":53415100,"shares":66736056,"eps":-3.105726,"marketStatus":"Post-Mkt","change":-1.1,"latestTime":"12-05 19:39:12 EST","open":105.7,"high":106.755,"low":103.59,"amount":56581281.125089996,"amplitude":0.029943,"askPrice":105,"askSize":20,"bidPrice":103.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.105726,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764982800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":105.7,"preHourTrading":{"tag":"盘前","latestPrice":105.68,"preClose":105.7,"latestTime":"09:00 EST","volume":85,"amount":8981.80975,"timestamp":1764943225668},"postHourTrading":{"tag":"盘后","latestPrice":104.6,"preClose":104.6,"latestTime":"17:01 EST","volume":5995,"amount":627039.80702,"timestamp":1764972074102},"volumeRatio":0.693411,"impliedVol":0.8685,"impliedVolPercentile":0.9},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2589273835","title":"The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589273835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589273835?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:10","pubTimestamp":1764864600,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU2023250843.SGD","IE00BN8TJ469.HKD","LU2461242641.AUD","SG9999014567.USD","IE0002141913.USD","LU1057294990.SGD","LU0861579265.USD","SG9999015341.SGD","IE00B2B36J28.USD","LU1291159041.SGD","LU0211331839.USD","LU1585245621.USD","LU2106854487.HKD","LU1934455863.HKD","BK4585","LU1066053197.SGD","LU1571399168.USD","BK4588","LU1941712264.USD","XBI","LU1037948541.HKD","SG9999015358.SGD","ISBC","LU1066051225.USD","LU1093756168.USD","LU1983299246.USD","LU2112291526.USD","LU0266013472.USD","MRK","SG9999014559.SGD","IE00B1BXHZ80.USD","BK4516","LU0238689110.USD","ASND","LU0320765992.SGD","LU1934455277.USD","CDTX","IE00BBT3K403.USD","LU2361045086.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","RYTM","LU0070302665.USD","LU1989772840.SGD","LU2023250504.SGD","LU1162221912.USD","LU1989772923.USD","LU1061106388.HKD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2587750173","title":"Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2587750173","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587750173?lang=en_us&edition=fundamental","pubTime":"2025-11-29 16:20","pubTimestamp":1764404428,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) shares are in focus after Citigroup initiated coverage with a Buy rating. This action joins a series of upbeat recommendations that highlight institutional optimism around the company’s long-term growth story and pipeline.\nSee our latest analysis for Rhythm Pharmaceuticals.\nMomentum has clearly been building for Rhythm Pharmaceuticals, with recent gains such as the 7.2% share price return over the past week and a strong year-to-date price run of 81.6%. These...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-assessing-valuation-as-citigroup","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-assessing-valuation-as-citigroup","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RYTM"],"gpt_icon":0},{"id":"2586216511","title":"How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2586216511","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586216511?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:27","pubTimestamp":1764210430,"startTime":"0","endTime":"0","summary":"In recent days, Rhythm Pharmaceuticals received a wave of positive attention after Citigroup analyst Samantha Semenkow initiated coverage with a \"Buy\" rating, reflecting growing consensus sentiment from multiple brokerages.\nThis surge in optimistic analyst outlooks highlights increasing confidence in Rhythm Pharmaceuticals' potential for growth and innovation within the rare disease biopharmaceutical sector.\nWe'll explore how this increase in favorable analyst coverage could influence the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-positive-analyst-coverage-at-rhythm-pharmaceuticals-rytm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-positive-analyst-coverage-at-rhythm-pharmaceuticals-rytm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"2586479004","title":"Rhythm Pharmaceuticals Initiated at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479004?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:26","pubTimestamp":1764080760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:26 ET (14:26 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","RYTM","BK4585"],"gpt_icon":0},{"id":"2586647354","title":"Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2586647354","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586647354?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:59","pubTimestamp":1764075555,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $126.31, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"2586990422","title":"Rhythm Pharmaceuticals initiated with a Buy at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2586990422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586990422?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:05","pubTimestamp":1764068711,"startTime":"0","endTime":"0","summary":"Citi initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $136 price target The firm says Rhythm is a commercial-stage biotech...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-a-buy-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-a-buy-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","RYTM","BK4139"],"gpt_icon":0},{"id":"2586490164","title":"Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586490164","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586490164?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:16","pubTimestamp":1764018965,"startTime":"0","endTime":"0","summary":"Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5SMpNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"2585464366","title":"S&P 500 Futures Climb In Premarket Trading; Centene, Millicom Intl Cellular Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464366?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:31","pubTimestamp":1763987460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Centene Corp.  was up 7.1% in pre-market trading, and Millicom International Cellular S.A.  was up 5.6%.Molina Healthcare Inc. , Biogen Inc. , and Life360 Inc.  were all posting gains of at least 5%. In early trading, McCormick & Co. Inc.  and Rhythm Pharmaceuticals Inc.  had posted declines, falling 5.4% and 2.8%, respectively.Meanwhile S&P 500 futures were up 0.34%, with futures for the Dow Jones Industrial Average rising 0.06%. The Cboe Volatility Index futures were down 6.03%.In commodities news, Brent crude oil futures were down 0.23%, and gold futures were down 0.35%. Bitcoin slipped 1.77% to $85,912.In the previous regular trading session, the S&P 500 and the Dow were up 0.98% and 1.08%, respectively. In Asia overnight, China's Shanghai Composite Index was up 0.05%.In afternoon trading, stocks in Europe are up, with the STOXX Europe 6","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613",".SPX","BK4597","GB00B4LPDJ14.GBP","OEX","LU0130103400.USD","CNC","LU0477156953.USD","LU0109394709.USD","LU0648000940.SGD","LU1201861249.SGD","MOH","TIGO","MESmain","OEF","SPY","SG9999014005.SGD","VOO","IE00B19Z9Z06.USD","BIIB","LU0742534661.SGD","LU2404859667.USD","LIF","SDS","SPXU","BK4132","BK4581","GB00B4QBRK32.GBP","SG9999014013.SGD","MKC","BK4588","LU1989771016.USD","BK4550","BK4139","LU0690374961.EUR","UPRO","SSO","LU0477156797.USD","SG9999014021.USD","LU0980610538.SGD","RYTM","LU0130518102.USD","ESmain","LU0130517989.USD","BK4023","LU1291159041.SGD","LU2362541513.USD","LU0130102774.USD","IVV","SH"],"gpt_icon":0},{"id":"2584929705","title":"Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929705","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929705?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:06","pubTimestamp":1763571975,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Rhythm Pharmaceuticals Inc ::*RHYTHM PHARMACEUTICALS ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR IMCIVREE (SETMELANOTIDE) FOR PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY*RHYTHM PHAR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3PkKTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RYTM","BK4139"],"gpt_icon":0},{"id":"2584675832","title":"FDA Review Extension for IMCIVREE Might Change the Case for Investing in Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584675832","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584675832?lang=en_us&edition=fundamental","pubTime":"2025-11-17 23:26","pubTimestamp":1763393173,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals recently announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide) in acquired hypothalamic obesity, moving the PDUFA goal date from December 20, 2025, to March 20, 2026, after requesting further sensitivity analyses on clinical efficacy data.\nThis regulatory update was classified as a major amendment but did not involve new data submissions or concerns related to safety or manufacturing,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/fda-review-extension-for-imcivree-might-change-the-case-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/fda-review-extension-for-imcivree-might-change-the-case-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4543","RYTM","BK4023","BK4588","BK4139","BK4528","BK4587","BK4551"],"gpt_icon":1},{"id":"2584623857","title":"S&P 500 Futures Up In Premarket Trading; Jazz Pharmaceuticals, Clearwater Analytics Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584623857?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:31","pubTimestamp":1763382660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Jazz Pharmaceuticals PLC  was up 21.8% in pre-market trading, and Clearwater Analytics Holdings Inc.  was up 12.0%.Rhythm Pharmaceuticals Inc. , Elbit Systems Ltd. , and Figure Technology Solutions Inc.  were all posting gains of at least 5%. In early trading, Liberty Media Corp. Series A Liberty Live  and Dell Technologies Inc. Cl C  had posted declines, falling 8.3% and 6.3%, respectively.Meanwhile S&P 500 futures were up 0.12%, with futures for the Dow Jones Industrial Average falling 0.05%. The Cboe Volatility Index futures were down 0.98%.In commodities news, Brent crude oil futures were down 0.14%, and gold futures were down 0.38%. Bitcoin was up 1.40% to $95,395.In the previous regular trading session, the S&P 500 and the Dow were down 0.05% and 0.65%, respectively. Stocks in Asia were down overnight, with Japan's NIKKEI 225 Index dow","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","BK4516","BK4532","ESmain","LU1267930227.SGD","UPRO","BK4550","LU0109394709.USD","LU0267386448.USD","BK4023","BK4534","ESLT","OEX","RYTM","LU0823416689.USD","LU0889565916.HKD","BK4139","SSO","LU1235294995.USD","BK4007","DELL","BK4588","SPY","BK4533","IVV","LU0976567544.SGD","LU1823568750.SGD","JAZZ","LU0128525689.USD","LLYVA","SPXU","BK4211","MESmain","BK4585","OEF","CWAN","IE00BN0W2W23.USD","BK4170","LU1046421795.USD","SH","VOO","BK4543","SDS","LU0320765992.SGD","BK4187","BK4581","LU0211326755.USD",".SPX","LU2065731478.USD"],"gpt_icon":1},{"id":"2582807830","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807830","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807830?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:46","pubTimestamp":1762807560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 15:46 ET (20:46 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2582736148","title":"Rhythm Pharmaceuticals Reports Setmelanotide Significantly Reduces BMI in Hypothalamic Obesity Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736148","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736148?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:01","pubTimestamp":1762776074,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. announced the presentation of four datasets at ObesityWeek 2025, including results from the Phase 3 TRANSCEND trial evaluating setmelanotide in patients with acquired hypothalamic obesity. Data presented showed that setmelanotide achieved significant reductions in BMI, both in patients receiving concomitant GLP-1 therapy and those not on GLP-1 therapy. Additional analyses indicated clinically meaningful improvements in cardiometabolic parameters after 52 weeks of setmelanotide treatment. Patient and caregiver interviews from the TRANSCEND trial also reported beneficial changes in hunger, weight, energy levels, and physical activity. The results were presented at ObesityWeek 2025 in Atlanta, GA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL3mS4Bw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","RYTM","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4139","LU2095319765.USD","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582878017","title":"Rhythm Pharmaceuticals price target raised to $114 from $105 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582878017?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:51","pubTimestamp":1762775461,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $114 from $105 and keeps a Buy rating on the shar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-114-from-105-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-114-from-105-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","RYTM","BK4139"],"gpt_icon":0},{"id":"2582810676","title":"Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810676?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:10","pubTimestamp":1762740615,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), Eli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-rhythm-pharmaceuticals-rytm-eli-lilly-co-lly-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-rhythm-pharmaceuticals-rytm-eli-lilly-co-lly-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0471298694.HKD","LU1868836757.USD","IE00BJT1NW94.SGD","LU2456880835.USD","RYTM","XBI","LU1974910355.USD","LU2360106947.USD","LU2471134523.USD","LU2746668461.USD","BK4137","LABU","SGXZ99366536.SGD","LU2552382132.HKD","LU0238689110.USD","LU0256863902.USD","HCSG","LU0820561818.USD","LU1280957306.USD","LU1291159041.SGD","LU0234572021.USD","LU0128526141.USD","LU1093756325.SGD","LU2552382058.USD","LU0058720904.USD","LU0266013472.USD","LU2552382215.SGD","LU2750360997.AUD","LU0203201768.USD","LU1983299246.USD","SGXZ31699556.SGD","BK4007","LU0353189680.USD","LU1267930730.SGD","LU2237443622.USD","IE00B2B36J28.USD","BK4516","XLV","LLY","LU1917777945.USD","SG9999017495.SGD","LU1868836914.USD","IE0009355771.USD","LU0823416689.USD","LU0106261372.USD","LU2361044865.SGD","LU2471134879.HKD","LU0471298777.SGD","SG9999015952.SGD","BK4581"],"gpt_icon":0},{"id":"2581836678","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2581836678","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581836678?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:54","pubTimestamp":1762545240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 14:54 ET (19:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RYTM","BK4139"],"gpt_icon":0},{"id":"2581583519","title":"Sector Update: Health Care Stocks Retreat Friday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2581583519","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581583519?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:01","pubTimestamp":1762542087,"startTime":"0","endTime":"0","summary":"Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each shedding about 0.5%.The iShares Biotechnology ETF  fell 1.5%.In corporate news, Gilead Sciences  shares dropped 3.3% after the company said a phase 3 trial comparing its drug Trodelvy with chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer did not meet the primary endpoint of progression-free survival.Moderna  continues to target cash breakeven in 2028, banking on its ongoing cost reductions and revenue growth from geographic expansion and new product launches, Morgan Stanley said in a Friday note. The firm maintained its equalweight rating on Moderna but adjusted its price target to $30 from $32. Moderna shares were down 1.7%.Rhythm Pharmaceuticals  said the US Food and Drug Administration extended the review period for its supplemental new drug application for Imcivree, or setmelanotide, for treating a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0267386448.USD","LU0971096721.USD","BK4588","LU1571399168.USD","RYTM","IBB","LU1244550494.USD","XBI","LU1548497426.USD","BK4533","BK4566","LU1720051017.SGD","IE00B7SZLL34.SGD","MRNA","LU2133065610.SGD","LU1674673428.USD","LABU","LU0158827781.USD","BK4127","LU1074936037.SGD","LU1066053197.SGD","LU0106261372.USD","LU0098860793.USD","LU2089283258.USD","LU0882574055.USD","LU1778281490.HKD","BK4548","GILD","LU0114720955.EUR","LU2347655156.SGD","LU0795875086.SGD","LU0889565916.HKD","LU1989772840.SGD","LU2023251221.USD","SG9999015986.USD","XLV","LU2357305700.SGD","LU0912757837.SGD","BK4568","LU1244550221.USD","LU2468319806.SGD","BK4581","LU0234570918.USD","LU0823416689.USD","LU0795875169.SGD","SG9999015945.SGD","LU0289739699.SGD","BK4139","LU0106831901.USD","LU2271345857.HKD"],"gpt_icon":1},{"id":"2581882715","title":"BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882715?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:01","pubTimestamp":1762531314,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton InteractiveEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL6N3WJ0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCHP","NEM","VOYG","OGN","HL","MNST","INKT","LDOS","RYTM","KKR","HAE","GIFI","CMI","INOD","ABNB","BK4187","RRR","CE","AKAM","DKNG","TXG","WEN","CEG","TASK","ANIP","IE00B19Z9Z06.USD","AIRS","OLED","XYZ","FROG","GMED","NTLA","CDE","AFRM","FLGT","GRND","TSYW.SI","CNH","PTON","FLR","TTD","SOLV"],"gpt_icon":1},{"id":"2581388952","title":"BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT","url":"https://stock-news.laohu8.com/highlight/detail?id=2581388952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581388952?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:22","pubTimestamp":1762525347,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHTEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL6N3WJ0KC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LASR","PTON","HL","KKR","AFRM","ANIP","IE00BYXW3230.USD","WEN","FLR","LDOS","GRND","LU1974910355.USD","AIRS","ABNB","TTD","CEG","LU0980610538.SGD","OLED","BK4559","LU0345774391.USD","CDE","VOYG","XYZ","TSYW.SI","LU2087621335.USD","INOD","IE00BD4GTT62.SGD","OGN","NEM","LU1046421795.USD","TXG","CNH","MCHP","IE00BD6J9T35.USD","RYTM","NTLA","AKAM","FLGT","BK4588","LU0868494617.USD","LU2417539215.USD","CMI","MNST"],"gpt_icon":1},{"id":"2581885487","title":"BUZZ-Rhythm falls after US FDA delays decision on drug for brain damage-related obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2581885487","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581885487?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:43","pubTimestamp":1762523005,"startTime":"0","endTime":"0","summary":"BUZZ-Rhythm falls after US FDA delays decision on drug for brain damage-related obesity** Shares of Rhythm Pharmaceuticals RYTM.O fall 3.6% to $95 premarket ** Drugmaker says U.S. FDA has pushed back a decision on expanding the use of its obesity drug Imcivree to December 20 after asking for more efficacy data in October** The additional information has been deemed a 'major amendment,' which allows for more time for the agency to review** U.S. FDA now plans to decide by March 20 on approving RYTM's Imcivree for hypothalamic obesity – Co** Hypothalamic obesity is a rare condition where damage to the brain's hypothalamus causes uncontrollable weight gain** Up to last close, stock up ~76% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL4N3WJ140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","RYTM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":0.0068},{"period":"3month","weight":0.0351},{"period":"6month","weight":0.5519},{"period":"1year","weight":0.7509},{"period":"ytd","weight":0.8882}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.053118},{"month":2,"riseRate":0.375,"avgChangeRate":-0.043141},{"month":3,"riseRate":0.125,"avgChangeRate":-0.055987},{"month":4,"riseRate":0.625,"avgChangeRate":0.023443},{"month":5,"riseRate":0.25,"avgChangeRate":-0.062002},{"month":6,"riseRate":0.5,"avgChangeRate":0.046517},{"month":7,"riseRate":0.5,"avgChangeRate":0.281728},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.039954}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction